Irinotecan

Generic Name: Irinotecan

Brand Names: Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₈N_₄O_₆

CAS Number: 97682-44-5

Unique Ingredient Identifier: 7673326042

Background: Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Indication: For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

Irinotecan in Treating Patients With Stage IV or Recurrent Soft Tissue Sarcoma

Phase 2

Conditions: Sarcoma

First Posted Date: 2004-04-14

Last Posted Date: 2014-01-06

Lead Sponsor: Herbert Irving Comprehensive Cancer Center

Target Recruit Count: 27

Registration Number: NCT00003719

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center, New York, New York, United States

Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer

Phase 3

Conditions: Colorectal Cancer

First Posted Date: 2004-04-13

Last Posted Date: 2013-12-19

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00021281

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer

Phase 3

Completed

Conditions: Colorectal Cancer

First Posted Date: 2004-04-12

Last Posted Date: 2012-09-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 430

Registration Number: NCT00004885

Locations: 🇪🇬
National Cancer Institute of Egypt, Cairo, Egypt
🇩🇪
St. Johannes Hospital - Medical Klinik II, Duisburg, Germany
🇩🇪
Universitaetsklinik und Strahlenklinik - Essen, Essen, Germany

and more 54 locations

Irinotecan in Treating Patients With Recurrent Malignant Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-04-09

Last Posted Date: 2013-06-21

Lead Sponsor: New Approaches to Brain Tumor Therapy Consortium

Registration Number: NCT00003301

Locations: 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

and more 6 locations

Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-04-09

Last Posted Date: 2012-08-09

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 12

Registration Number: NCT00003710

Locations: 🇺🇸
San Antonio Cancer Institute, San Antonio, Texas, United States

Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: fluorouracil
Drug: irinotecan hydrochloride
Drug: leucovorin calcium
Drug: oxaliplatin

First Posted Date: 2004-04-08

Last Posted Date: 2016-12-07

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 14

Registration Number: NCT00080951

Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Radiation: Radiation Therapy
Drug: Capecitabine 1200 mg/m^2/day
Drug: Capecitabine 1650 mg/m^2/day
Drug: Oxaliplatin
Drug: Irinotecan
Procedure: Surgery
Drug: Folinic Acid
Drug: Fluorouracil

First Posted Date: 2004-04-08

Last Posted Date: 2020-02-27

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 146

Registration Number: NCT00081289

Locations: 🇺🇸
Baptist-South Miami Regional Cancer Program, Miami, Florida, United States
🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸
Ingalls Cancer Care Center at Ingalls Memorial Hospital, Harvey, Illinois, United States

and more 2 locations